Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Enrollment and transition challenges in the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) network's PROMISE trial for resource-limited regions.

Angelidou K, Fowler MG, Flynn P, Coletti A, McCarthy K, Browning R, McIntyre J, Brummel SS, Shapiro DE, Tierney C; PROMISE study team.

Clin Trials. 2020 Mar 19:1740774520912428. doi: 10.1177/1740774520912428. [Epub ahead of print]

PMID:
32191142
2.

Hepatotoxicity and Liver-Related Mortality in Women of Child-Bearing Potential Living With HIV and High CD4 Counts Initiating Efavirenz-Containing Regimens.

Bhattacharya D, Gupta A, Tierney C, Huang S, Peters MG, Chipato T, Martinson F, Mohtashemi N, Dula D, George K, Chaktoura N, Klingman K, Gnanashanmugam D, Currier JS, Fowler MG.

Clin Infect Dis. 2020 Mar 12. pii: ciaa244. doi: 10.1093/cid/ciaa244. [Epub ahead of print]

PMID:
32161944
3.

The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial.

Atuhaire P, S Brummel S, Mmbaga BT, Angelidou K, Fairlie L, Violari A, Theron G, Mukuzunga C, Mawlana S, Mubiana-Mbewe M, Naidoo M, Makanani B, Mandima P, Nematadzira T, Suryavanshi N, Mbengeranwa T, Loftis A, Basar M, McCarthy K, Currier JS, Fowler MG; 1077BF/1077FF PROMISE Team.

PLoS One. 2020 Jan 30;15(1):e0228003. doi: 10.1371/journal.pone.0228003. eCollection 2020.

4.

Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.

Aizire J, Brooks KM, Mirochnick M, Flynn PM, Butler K, Kiser JJ, Siberry GK, Fenton T, Cababasay M, Fowler MG; PROMISE Study Team.

J Acquir Immune Defic Syndr. 2020 Feb 1;83(2):173-180. doi: 10.1097/QAI.0000000000002247.

PMID:
31929405
5.

Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.

Venkatesh KK, Farhad M, Fenton T, Moodley D, Naik S, Nakabiito C, Fairlie L, Fowler MG, Stringer JSA, Chi BH.

AIDS. 2019 Dec 1;33(15):2403-2413. doi: 10.1097/QAD.0000000000002367.

PMID:
31764105
6.

Factors associated with unsuppressed viremia in women living with HIV on lifelong ART in the multi-country US-PEPFAR PROMOTE study: A cross-sectional analysis.

Atuhaire P, Hanley S, Yende-Zuma N, Aizire J, Stranix-Chibanda L, Makanani B, Milala B, Cassim H, Taha T, Fowler MG.

PLoS One. 2019 Oct 24;14(10):e0219415. doi: 10.1371/journal.pone.0219415. eCollection 2019.

7.

Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study.

Hompe ED, Jacobson DL, Eudailey JA, Butler K, Edwards W, Pollara J, Brummel SS, Fouda GG, Chinula L, Kamanga M, Kinikar A, Moodley D, Owor M, Fowler MG, Permar SR.

mSphere. 2019 Oct 23;4(5). pii: e00716-19. doi: 10.1128/mSphere.00716-19.

8.

Decreased growth among antiretroviral drug and HIV-exposed uninfected versus unexposed children in Malawi and Uganda.

Aizire J, Sikorskii A, Ogwang LW, Kawalazira R, Mutebe A, Familiar-Lopez I, Mallewa M, Taha T, Boivin MJ, Fowler MG; PROMISE-NEURODEV study team.

AIDS. 2020 Feb 1;34(2):215-225. doi: 10.1097/QAD.0000000000002405.

PMID:
31634154
9.

Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.

Onyango-Makumbi C, Owora AH, Mwiru RS, Mwatha A, Young AM, Moodley D, Coovadia HM, Stranix-Chibanda L, Manji K, Maldonado Y, Richardson P, Andrew P, George K, Fawzi W, Fowler MG.

J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):377-385. doi: 10.1097/QAI.0000000000002145.

PMID:
31567725
10.

Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.

Venkatesh KK, Farhad M, Fenton T, Moodley D, Naik S, Nakabiito C, Fairlie L, Fowler MG, Stringer JSA, Chi BH.

AIDS. 2019 Sep 3. doi: 10.1097/QAD.0000000000002367. [Epub ahead of print]

PMID:
31490232
11.

Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe.

Stranix-Chibanda L, Brummel S, Pilotto J, Mutambanengwe M, Chanaiwa V, Mhembere T, Kamateeka M, Aizire J, Masheto G, Chamanga R, Maluwa M, Hanley S, Joao E, Theron G, Nevrekar N, Nyati M, Santos B, Aurpibul L, Mubiana-Mbewe M, Oliveira R, Anekthananon T, Mlay P, Angelidou K, Tierney C, Ziemba L, Coletti A, McCarthy K, Basar M, Chakhtoura N, Browning R, Currier J, Fowler MG, Flynn P; PROMISE study team.

AIDS Behav. 2019 Sep;23(9):2522-2531. doi: 10.1007/s10461-019-02624-3.

12.

Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men.

Le CN, Britto P, Brummel SS, Hoffman RM, Li JZ, Flynn PM, Taha TE, Coletti A, Fowler MG, Bosch RJ, Gandhi RT, Klingman KL, McIntyre JA, Currier JS.

AIDS. 2019 Nov 15;33(14):2149-2156. doi: 10.1097/QAD.0000000000002334.

PMID:
31373919
13.

Risk Factors for Adverse Birth Outcomes in the PROMISE 1077BF/1077FF Trial.

Sebikari D, Farhad M, Fenton T, Owor M, Stringer JSA, Qin M, Chakhtoura N, Chi BH, Saidi F, Nevrekar N, Violari A, Chipato T, McIntyre JA, Moodley D, Taha TE, Theron G, Fowler MG.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):521-532. doi: 10.1097/QAI.0000000000002072.

PMID:
31295174
14.

Depot medroxyprogesterone acetate and the vaginal microbiome as modifiers of tenofovir diphosphate and lamivudine triphosphate concentrations in the female genital tract of Ugandan women: Implications for TDF/3TC in pre-exposure prophylaxis.

Nicol MR, Eneh P, Nakalega R, Kaiser T, Kabwigu S, Isingel E, Beksinska M, Sykes C, Fowler MG, Brown TT, Staley C, Kiweewa Matovu F.

Clin Infect Dis. 2019 May 25. pii: ciz443. doi: 10.1093/cid/ciz443. [Epub ahead of print]

PMID:
31131846
15.

Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.

Boivin MJ, Maliwichi-Senganimalunje L, Ogwang LW, Kawalazira R, Sikorskii A, Familiar-Lopez I, Kuteesa A, Nyakato M, Mutebe A, Namukooli JL, Mallewa M, RuiseƱor-Escudero H, Aizire J, Taha TE, Fowler MG.

Lancet HIV. 2019 Aug;6(8):e518-e530. doi: 10.1016/S2352-3018(19)30083-9. Epub 2019 May 20.

PMID:
31122797
16.

Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women.

Murnane PM, Bacchetti P, Currier JS, Brummel S, Okochi H, Phung N, Louie A, Kuncze K, Hoffman RM, Nematadzira T, Soko DK, Owor M, Saidi F, Flynn PM, Fowler MG, Gandhi M.

AIDS. 2019 Aug 1;33(10):1657-1662. doi: 10.1097/QAD.0000000000002237.

PMID:
31021852
17.

Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial.

Hoffman RM, Angelidou KN, Brummel SS, Saidi F, Violari A, Dula D, Mave V, Fairlie L, Theron G, Kamateeka M, Chipato T, Chi BH, Stranix-Chibanda L, Nematadzira T, Moodley D, Bhattacharya D, Gupta A, Coletti A, McIntyre JA, Klingman KL, Chakhtoura N, Shapiro DE, Fowler MG, Currier JS; IMPAACT PROMISE 1077BF/FF team.

HIV Clin Trials. 2018 Dec;19(6):209-224. doi: 10.1080/15284336.2018.1537327.

18.

Primary HIV prevention in pregnant and lactating Ugandan women: A randomized trial.

Homsy J, King R, Bannink F, Namukwaya Z, Vittinghof E, Amone A, Ojok F, Rukundo G, Amama S, Etima J, Matovu J, Weissglas F, Ojom L, Atim P, Darbes L, Byamugisha J, Rutherford G, Katabira E, Fowler MG; PRIMAL Study Team.

PLoS One. 2019 Feb 25;14(2):e0212119. doi: 10.1371/journal.pone.0212119. eCollection 2019.

19.

The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings.

Taha TE, Yende-Zuma N, Aizire J, Chipato T, Wambuzi Ogwang L, Makanani B, Chinula L, Nyati MM, Hanley S, Brummel SS, Fowler MG.

PLoS One. 2018 Dec 13;13(12):e0208805. doi: 10.1371/journal.pone.0208805. eCollection 2018.

20.

Comparative effects of three methods of promoting breastfeeding among human immunodeficiency virus-infected women in Uganda: a parallel randomized clinical trial.

Namale-Matovu J, Owora AH, Onyango-Makumbi C, Mubiru M, Namuli PE, Motevalli-Oliner M, Musoke P, Nolan M, Fowler MG.

Int Health. 2018 Nov 1;10(6):430-441. doi: 10.1093/inthealth/ihy041.

21.

What is new in perinatal HIV prevention?

Fowler MG, Flynn P, Aizire J.

Curr Opin Pediatr. 2018 Feb;30(1):144-151. doi: 10.1097/MOP.0000000000000579. Review.

22.

Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial.

Flynn PM, Taha TE, Cababasay M, Fowler MG, Mofenson LM, Owor M, Fiscus S, Stranix-Chibanda L, Coutsoudis A, Gnanashanmugam D, Chakhtoura N, McCarthy K, Mukuzunga C, Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga BT, Masenya M, Nyati M, Theron G, Mulenga H, Butler K, Shapiro DE; PROMISE Study Team.

J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):383-392. doi: 10.1097/QAI.0000000000001612.

23.

Time to first positive HIV-1 DNA PCR may differ with antiretroviral regimen in infants infected with non-B subtype HIV-1.

Balasubramanian R, Fowler MG, Dominguez K, Lockman S, Tookey PA, Huong NNG, Nesheim S, Hughes MD, Lallemant M, Tosswill J, Shaffer N, Sherman G, Palumbo P, Shapiro DE.

AIDS. 2017 Nov 28;31(18):2465-2474. doi: 10.1097/QAD.0000000000001640.

24.

Multicountry Validation of SAMBA - A Novel Molecular Point-of-Care Test for HIV-1 Detection in Resource-Limited Setting.

Ondiek J, Namukaya Z, Mtapuri-Zinyowera S, Balkan S, Elbireer A, Ushiro Lumb I, Kiyaga C, Goel N, Ritchie A, Ncube P, Omuomu K, Ndiege K, Kekitiinwa A, Mangwanya D, Fowler MG, Nadala L, Lee H.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):e52-e57. doi: 10.1097/QAI.0000000000001476.

PMID:
28902680
25.

Greater involvement of HIV-infected peer-mothers in provision of reproductive health services as "family planning champions" increases referrals and uptake of family planning among HIV-infected mothers.

Mudiope P, Musingye E, Makumbi CO, Bagenda D, Homsy J, Nakitende M, Mubiru M, Mosha LB, Kagawa M, Namukwaya Z, Fowler MG.

BMC Health Serv Res. 2017 Jun 27;17(1):444. doi: 10.1186/s12913-017-2386-x.

26.

Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial.

Akello CA, Bunge KE, Nakabiito C, Mirembe BG, Fowler MG, Mishra A, Marrazzo J, Chirenje ZM, Celum C, Balkus JE.

J Womens Health (Larchmt). 2017 Jun;26(6):670-676. doi: 10.1089/jwh.2016.5958. Epub 2017 Feb 17.

27.

Antiretroviral Therapy for Perinatal HIV Prevention.

Fowler MG, Mofenson LM, Taha TE.

N Engl J Med. 2017 Feb 16;376(7):699-700. doi: 10.1056/NEJMc1616287. No abstract available.

PMID:
28199813
28.

Ontogeny of CD4+ T Lymphocytes With Phenotypic Susceptibility to HIV-1 During Exclusive and Nonexclusive Breastfeeding in HIV-1-Exposed Ugandan Infants.

McFarland EJ, Powell TM, Onyango-Makumbi C, Zhang W, Melander K, Naluyima P, Okurut S, Eller MA, Fowler MG, Janoff EN.

J Infect Dis. 2017 Feb 1;215(3):368-377. doi: 10.1093/infdis/jiw553.

29.

Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.

Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, McIntyre J, Gnanashanmugam D, Siberry GK, Coletti AS, Taha TE, Klingman KL, Martinson FE, Owor M, Violari A, Moodley D, Theron GB, Bhosale R, Bobat R, Chi BH, Strehlau R, Mlay P, Loftis AJ, Browning R, Fenton T, Purdue L, Basar M, Shapiro DE, Mofenson LM; IMPAACT 1077BF/1077FF PROMISE Study Team.

N Engl J Med. 2016 Nov 3;375(18):1726-1737.

30.

Mother-to-Child HIV-1 Transmission Events Are Differentially Impacted by Breast Milk and Its Components from HIV-1-Infected Women.

Shen R, Achenbach J, Shen Y, Palaia J, Rahkola JT, Nick HJ, Smythies LE, McConnell M, Fowler MG, Smith PD, Janoff EN.

PLoS One. 2015 Dec 17;10(12):e0145150. doi: 10.1371/journal.pone.0145150. eCollection 2015.

31.

Use of peers, community lay persons and Village Health Team (VHT) members improves six-week postnatal clinic (PNC) follow-up and Early Infant HIV Diagnosis (EID) in urban and rural health units in Uganda: A one-year implementation study.

Namukwaya Z, Barlow-Mosha L, Mudiope P, Kekitiinwa A, Matovu JN, Musingye E, Ssebaggala JN, Nakyanzi T, Abwooli JJ, Mirembe D, Etima J, Bitarakwate E, Fowler MG, Musoke PM; Peer-senga study Group at Mulago, Mengo, Rubaga and Mpigi Health Units.

BMC Health Serv Res. 2015 Dec 15;15:555. doi: 10.1186/s12913-015-1213-5.

32.

Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004-2009.

Schwartz SR, Kumwenda N, Kumwenda J, Chen S, Mofenson LM, Taylor AW, Fowler MG, Taha TE.

Matern Child Health J. 2016 Mar;20(3):542-9. doi: 10.1007/s10995-015-1852-5.

33.

A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study".

Kiweewa FM, Bakaki PM, McConnell MS, Musisi M, Namirembe C, Nakayiwa F, Kusasira F, Nakintu D, Mubiru MC, Musoke P, Fowler MG.

BMC Public Health. 2015 Sep 29;15:988. doi: 10.1186/s12889-015-2345-6.

34.

Impaired haemophilus influenzae type b transplacental antibody transmission and declining antibody avidity through the first year of life represent potential vulnerabilities for HIV-exposed but -uninfected infants.

Gaensbauer JT, Rakhola JT, Onyango-Makumbi C, Mubiru M, Westcott JE, Krebs NF, Asturias EJ, Fowler MG, McFarland E, Janoff EN.

Clin Vaccine Immunol. 2014 Dec;21(12):1661-7. doi: 10.1128/CVI.00356-14. Epub 2014 Oct 8.

35.

Factors Determining Survival and Retention among HIV-Infected Children and Adolescents in a Community Home-Based Care and a Facility-Based Family-Centred Approach in Kampala, Uganda: A Cohort Study.

Massavon W, Barlow-Mosha L, Mugenyi L, McFarland W, Gray G, Lundin R, Costenaro P, Nannyonga MM, Penazzato M, Bagenda D, Namisi CP, Wabwire D, Mubiru M, Kironde S, Bilardi D, Mazza A, Fowler MG, Musoke P, Giaquinto C.

ISRN AIDS. 2014 Apr 1;2014:852489. doi: 10.1155/2014/852489. eCollection 2014.

36.

HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission.

Voronin Y, Mofenson LM, Cunningham CK, Fowler MG, Kaleebu P, McFarland EJ, Safrit JT, Graham BS, Snow W.

PLoS Med. 2014 Apr 8;11(4):e1001616. doi: 10.1371/journal.pmed.1001616. eCollection 2014 Apr.

37.

Neutralization of HIV subtypes A and D by breast milk IgG from women with HIV infection in Uganda.

Palaia JM, McConnell M, Achenbach JE, Gustafson CE, Stoermer KA, Nolan M, Guay LA, Leitner TK, Matovu F, Taylor AW, Fowler MG, Janoff EN.

J Infect. 2014 Mar;68(3):264-72. doi: 10.1016/j.jinf.2013.11.002. Epub 2013 Nov 13.

38.

Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial.

Fowler MG, Coovadia H, Herron CM, Maldonado Y, Chipato T, Moodley D, Musoke P, Aizire J, Manji K, Stranix-Chibanda L, Fawzi W, Chetty V, Msweli L, Kisenge R, Brown E, Mwatha A, Eshleman SH, Richardson P, Allen M, George K, Andrew P, Zwerski S, Mofenson LM, Jackson JB; HPTN 046 Protocol Team.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):366-74. doi: 10.1097/QAI.0000000000000052.

39.

Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival.

Owor M, Mwatha A, Donnell D, Musoke P, Mmiro F, Allen M, Jackson JB, Fowler MG, Guay LA.

J Acquir Immune Defic Syndr. 2013 Dec 15;64(5):464-71. doi: 10.1097/QAI.0000000000000015.

40.

Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.

Kaleebu P, Njai HF, Wang L, Jones N, Ssewanyana I, Richardson P, Kintu K, Emel L, Musoke P, Fowler MG, Ou SS, Jackson JB, Guay L, Andrew P, Baglyos L, Cao H; HPTN 027 protocol team.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):268-77. doi: 10.1097/01.qai.0000435600.65845.31.

41.

Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.

Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, Pinto J, Santos B, Parsons T, Kearney B, Emel L, Herron C, Richardson P, Hudelson SE, Eshleman SH, George K, Fowler MG, Sato P, Mofenson L; HPTN 057 Protocol Team.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):33-41. doi: 10.1097/QAI.0b013e3182a921eb.

42.

Noninferiority of a task-shifting HIV care and treatment model using peer counselors and nurses among Ugandan women initiated on ART: evidence from a randomized trial.

Kiweewa FM, Wabwire D, Nakibuuka J, Mubiru M, Bagenda D, Musoke P, Fowler MG, Antelman G.

J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):e125-32. doi: 10.1097/QAI.0b013e3182987ce6.

PMID:
23807157
43.

Antibody maturation and viral diversification in HIV-infected women.

James MM, Laeyendecker O, Sun J, Hoover DR, Mullis CE, Cousins MM, Coates T, Moore RD, Kelen GD, Fowler MG, Kumwenda JJ, Mofenson LM, Kumwenda NI, Taha TE, Eshleman SH.

PLoS One. 2013;8(2):e57350. doi: 10.1371/journal.pone.0057350. Epub 2013 Feb 27.

44.
45.

The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.

Barlow-Mosha LN, Bagenda DS, Mudiope PK, Mubiru MC, Butler LM, Fowler MG, Musoke PM.

Afr Health Sci. 2012 Sep;12(3):249-58.

46.

Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine.

Mudiope PK, Kim S, Wabwire D, Nyende L, Bagenda D, Mubiru M, Mulira R, Elbireer S, Namukwaya Z, Fowler MG, Musoke P.

Trop Med Int Health. 2013 Mar;18(3):344-51. doi: 10.1111/tmi.12054. Epub 2013 Jan 4.

47.

Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa.

Kintu K, Andrew P, Musoke P, Richardson P, Asiimwe-Kateera B, Nakyanzi T, Wang L, Fowler MG, Emel L, Ou SS, Baglyos L, Gurunathan S, Zwerski S, Jackson JB, Guay L.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):1-8. doi: 10.1097/QAI.0b013e31827f1c2d.

48.

Distribution of haematological and chemical pathology values among infants in Malawi and Uganda.

Kumwenda NI, Khonje T, Mipando L, Nkanaunena K, Katundu P, Lubega I, Elbireer A, Bolton S, Bagenda D, Mubiru M, Fowler MG, Taha TE.

Paediatr Int Child Health. 2012;32(4):213-27. doi: 10.1179/2046905512Y.0000000034.

49.

CD4, viral load response, and adherence among antiretroviral-naive breast-feeding women receiving triple antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV in Kisumu, Kenya.

Okonji JA, Zeh C, Weidle PJ, Williamson J, Akoth B, Masaba RO, Fowler MG, Thomas TK.

J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):249-57.

PMID:
22692094
50.

Stavudine concentrations in women receiving postpartum antiretroviral treatment and their breastfeeding infants.

Fogel JM, Taha TE, Sun J, Hoover DR, Parsons TL, Kumwenda JJ, Mofenson LM, Fowler MG, Hendrix CW, Kumwenda NI, Eshleman SH, Mirochnick M.

J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):462-5.

Supplemental Content

Loading ...
Support Center